Sei Investments Co. Has $2.91 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sei Investments Co. grew its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 31.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,935 shares of the biotechnology company's stock after purchasing an additional 5,764 shares during the quarter. Sei Investments Co.'s holdings in Sarepta Therapeutics were worth $2,910,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Wellington Management Group LLP lifted its holdings in Sarepta Therapeutics by 32.3% during the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock worth $340,527,000 after purchasing an additional 665,087 shares during the last quarter. Soros Fund Management LLC acquired a new stake in shares of Sarepta Therapeutics during the third quarter worth $25,800,000. Swedbank AB bought a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $16,706,000. Allspring Global Investments Holdings LLC grew its stake in shares of Sarepta Therapeutics by 16,717.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company's stock valued at $10,602,000 after acquiring an additional 84,926 shares in the last quarter. Finally, Erste Asset Management GmbH increased its position in Sarepta Therapeutics by 11.3% during the fourth quarter. Erste Asset Management GmbH now owns 708,248 shares of the biotechnology company's stock worth $86,116,000 after acquiring an additional 72,183 shares during the period. Institutional investors and hedge funds own 86.68% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of research firms have issued reports on SRPT. Royal Bank of Canada downgraded shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and cut their price objective for the company from $161.00 to $87.00 in a report on Monday, March 31st. Deutsche Bank Aktiengesellschaft cut their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research note on Wednesday, March 19th. HC Wainwright upgraded Sarepta Therapeutics from a "sell" rating to a "neutral" rating and set a $75.00 target price for the company in a research report on Wednesday, April 2nd. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Finally, Scotiabank cut their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research report on Thursday, March 20th. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $163.18.

Sarepta Therapeutics Trading Up 12.9 %

NASDAQ:SRPT traded up $6.35 during mid-day trading on Wednesday, hitting $55.65. 4,269,441 shares of the company's stock were exchanged, compared to its average volume of 1,363,913. Sarepta Therapeutics, Inc. has a fifty-two week low of $47.29 and a fifty-two week high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $5.40 billion, a P/E ratio of 44.52 and a beta of 0.93. The company has a 50 day simple moving average of $90.64 and a 200-day simple moving average of $111.23.

Insider Activity

In related news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.